Related Experiment Videos
[Studies on the hypoglycemic effect of ginseng polypeptide]
1Department of Pharmacology, Academy of Traditional Chinese Medicine, Changchun.
Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|January 1, 1990
Summary
Ginseng polypeptide (GPP) effectively lowers blood sugar and liver glycogen in animal models. This compound from Panax ginseng shows low toxicity, offering potential therapeutic benefits for hyperglycemia.
Area of Science:
- Pharmacology
- Biochemistry
- Natural Products
Context:
- Panax ginseng C. A. Meyer is a well-known medicinal herb.
- Ginseng polypeptide (GPP) is a bioactive compound derived from ginseng roots.
- Hyperglycemia is a condition characterized by elevated blood glucose levels.
Purpose:
- To investigate the hypoglycemic and metabolic effects of Ginseng polypeptide (GPP).
- To evaluate the impact of GPP on blood glucose, liver glycogen, and blood lipid levels.
- To assess the efficacy of GPP in various experimental hyperglycemia models and determine its toxicity.
Summary:
- Intravenous administration of GPP (50-200 mg/kg) in rats reduced blood sugar and liver glycogen without affecting blood lipids.
- Daily subcutaneous injections of GPP (50 and 100 mg/kg) in mice for 7 days also decreased blood glucose and liver glycogen.
- GPP demonstrated efficacy in reducing hyperglycemia induced by adrenaline, glucose, and alloxan, with specific modulatory effects on glycogen metabolism and low observed toxicity (iv LD50 in mice: 1.62 g/kg).
Impact:
- Ginseng polypeptide (GPP) shows significant potential as a natural therapeutic agent for managing hyperglycemia.
- The findings suggest GPP's role in regulating glucose and glycogen metabolism.
- Low toxicity profile indicates a favorable safety margin for potential pharmaceutical development.